Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report - Impact of the Article 5(3) scientific opinion on nitrosamines
Advanced pharmaceutical formulation for targeted therapeutic intervention.
Source
European Medicines Agency
Additional Information
medication.label.product_type
variation-report
medication.label.permit_number
EMA/47245/2021
medication.label.permit_validity
First published: 2021-03-02T09:33:00Z
Documents
Related Medications
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
AI Voice
Listen to the article content live